Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics


Eton Pharmaceuticals, Inc. (ETON): $3.06

0.09 (+3.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ETON POWR Grades

  • ETON scores best on the Growth dimension, with a Growth rank ahead of 97.67% of US stocks.
  • The strongest trend for ETON is in Value, which has been heading up over the past 70 days.
  • ETON ranks lowest in Momentum; there it ranks in the 25th percentile.

ETON Stock Summary

  • ETON has a market capitalization of $73,361,407 -- more than approximately only 16.62% of US stocks.
  • ETON's went public 4.05 years ago, making it older than merely 20.14% of listed US stocks we're tracking.
  • For ETON, its debt to operating expenses ratio is greater than that reported by 25.39% of US equities we're observing.
  • If you're looking for stocks that are quantitatively similar to ETON PHARMACEUTICALS INC, a group of peers worth examining would be EVLV, YEXT, LZ, AQMS, and AVPT.
  • Visit ETON's SEC page to see the company's official filings. To visit the company's web site, go to www.etonpharma.com.

ETON Valuation Summary

  • In comparison to the median Healthcare stock, ETON's price/sales ratio is 20.83% lower, now standing at 3.8.
  • ETON's price/sales ratio has moved NA NA over the prior 49 months.

Below are key valuation metrics over time for ETON.

Stock Date P/S P/B P/E EV/EBIT
ETON 2022-11-25 3.8 6.8 -8.5 -8.6
ETON 2022-11-23 3.8 6.8 -8.5 -8.6
ETON 2022-11-22 3.8 6.8 -8.5 -8.6
ETON 2022-11-21 3.9 6.9 -8.6 -8.7
ETON 2022-11-18 3.9 6.8 -8.6 -8.7
ETON 2022-11-17 3.8 6.7 -8.4 -8.4

ETON's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ETON has a Quality Grade of C, ranking ahead of 51.85% of graded US stocks.
  • ETON's asset turnover comes in at 0.663 -- ranking 45th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ETON's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.663 0.885 -1.378
2021-03-31 0.639 0.867 -1.807
2020-12-31 0.002 -6.333 -4.051
2020-09-30 0.028 -0.053 -3.354
2020-06-30 0.037 -0.009 -4.187
2020-03-31 0.034 0.005 -4.883

ETON Price Target

For more insight on analysts targets of ETON, see our ETON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.5 (Moderate Buy)

ETON Stock Price Chart Interactive Chart >

Price chart for ETON

ETON Price/Volume Stats

Current price $3.06 52-week high $4.78
Prev. close $2.97 52-week low $1.95
Day low $2.94 Volume 48,355
Day high $3.06 Avg. volume 133,032
50-day MA $2.45 Dividend yield N/A
200-day MA $3.00 Market Cap 77.41M

Eton Pharmaceuticals, Inc. (ETON) Company Bio


Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.


ETON Latest News Stream


Event/Time News Detail
Loading, please wait...

ETON Latest Social Stream


Loading social stream, please wait...

View Full ETON Social Stream

Latest ETON News From Around the Web

Below are the latest news stories about ETON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ETON as an investment opportunity.

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

Yahoo | November 23, 2022

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

Yahoo | November 22, 2022

Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

Yahoo | November 16, 2022

Eton Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

Eton Pharmaceuticals ( NASDAQ:ETON ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.22m (up 315% from...

Yahoo | November 16, 2022

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 20% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Read More 'ETON' Stories Here

ETON Price Returns

1-mo 20.00%
3-mo 33.62%
6-mo 4.44%
1-year -21.54%
3-year -52.19%
5-year N/A
YTD -28.67%
2021 -47.23%
2020 12.92%
2019 17.65%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6737 seconds.